The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful drugs.
from WSJ.com: Markets http://ift.tt/2xhApJg
via https://ifttt.com/ IFTTT
No comments:
Post a Comment